Join our daily newsletter At The Bell to receive exclusive market insights
With more than 600k average monthly users on the HotCopper forums, each and every discussion can move markets. That’s why getting in front of those red-hot trends is key for every trader worth their salt. In this daily HotCopper Trends column, we break down the top Oz stocks through each trading day.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Amplia (ASX:ATX) has been up after it confirmed the signing of a supply agreement with Eli Lilly & Company. The clinical trial collaboration and supply agreement will evaluate the company’s investigational FAK inhibitor narmafotinib in combination with Lilly’s late-stage investigational next-gen KRAS inhibitor olomorasib.
CEO and MD, Dr Chris Burns, said the collaboration further extends narmafotinib beyond pancreatic and ovarian cancer into NSCLC, broadening Amplia’s clinical footprint and addressable opportunity
“This collaboration is an exciting new stage in the progression of narmafotinib. We and others have shown that the combination of FAK and KRAS inhibition can lead to improved outcomes, and we are excited to advance with this clinical study to explore the combination potential with olomorasib, Lilly’s leading KRAS G12C inhibitor currently undergoing two global phase three studies in NSCLC.”
ATX was up 7.41% to 14.5¢ at the time of going to press.
On the commodities side, Future Metals (ASX:FME) has commenced an updated scoping study for the Panton platinum group metals (PGM) project in Western Australia. The study builds on the previously released 2023 scoping study and work undertaken by the company over the last six months.
The study will evaluate two possible development pathways a standalone greenfield mining and processing infrastructure at the Panton project site and mining at Panton, with material transported for processing at the existing Savannah site.
MD, Keith Bowes, said the updated scoping study represents an important step in defining a practical and capital-efficient development pathway for Panton.
“Our recent mineral resource estimate, along with our strategic review, the Savannah engineering assessment, and the exclusivity agreement signed with Zeta, have provided the company with good optionality and a strong platform to evaluate two robust development options,” Mr Bowes said.
FME jumped 8.33% to 1.3c as we went to print.
And, Metallium (ASX:MTM) was popular on HotCopper on news it had signed its first commercial monetisation deal for the flash joule heating (FJH) platform.
The Australian producer revealed it had reached a twelve-month technology services agreement with Environmental Clean Technologies (ASX: ECT) to evaluate FJH – using rapid heating with chlorine – as a faster, more scalable alternative to conventional HF-based processing for producing ‘MXenes’, using Metallium’s Gator Point reactor systems and engineering support.
The total phase one consideration is for up to US$1.4 million, with US$500,000 payable unconditionally on execution. MD and CEO, Michael Walshe, said the agreement represents an important milestone in Metallium’s commercial evolution.
“While our primary focus remains building a leading US critical metals processing business, we have always believed flash joule heating is a platform technology capable of creating value well beyond metals extraction,” he said.
“This agreement represents the first commercial monetisation of that broader platform strategy and validates the significant investment we have made in developing our proprietary reactor technology, engineering capability and Gator Point Technology Campus.”
MTM was down 6.90% to 27.0¢ in morning trading.
Looking wider, the S&P/ASX 200 was up today, gaining 114 points, or +1.27%.
That’s Tuesday’s HotCopper Trends, I’m Colin Sandell-Hay - see you for close.
Join the discussion. See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
-1200x645-380x200.jpg)
